- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07825454
Pilot Study of Hydroxychloroquine for the Treatment of AIMSS (AIMSS)
A Phase II Single-Arm Pilot Study of Hydroxychloroquine for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome
The purpose of this study is to evaluate the effectiveness of hydroxychloroquine sulfate (a type of drug commonly used to treat joint pain caused by inflammation, swelling) in reducing joint pain associated with Aromatase Inhibitor Associated Musculoskeletal Syndrome (AIMSS) for patients with breast cancer.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Aromatase Inhibitor (AI) therapy is highly effective for post-menopausal, estrogen receptor (ER) positive breast cancer, yet the clinical effectiveness of AI therapy is limited by noncompliance and early treatment discontinuation due to musculoskeletal side effects, which include joint pain, joint stiffness, bone pain, muscle weakness, and myalgias. Methods to improve compliance to AI therapy have the potential to increase survival.
This study will look at hydroxychloroquine (HCQ), a disease-modifying antirheumatic drug (DMARD) with well-established anti-inflammatory and immunomodulatory properties. It is FDA-approved for the treatment of conditions characterized by chronic inflammatory joint pain similar to AIMSS. This single-arm, proof of concept study will look for an improvement in joint pain for patients undergoing standard of care treatment involving AI therapy.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Niraj Shah, MS
- Telefoonnummer: 317-278-3420
- E-mail: shahnir@iu.edu
Studie Locaties
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46202
- Werving
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center
-
Hoofdonderzoeker:
- Tarah Ballinger, MD
-
Contact:
- Niraj Shah, MS
- Telefoonnummer: 317-278-3420
- E-mail: shahnir@iu.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Age ≥ 18 years at the time of informed consent
-
Ability to provide written informed consent and HIPAA authorization
-
Diagnosis of DCIS or stage I, II, or III breast cancer
-
Currently receiving adjuvant aromatase inhibitor therapy (anastrozole, letrozole or exemestane) for ≥ 4 weeks prior to enrollment Note: Concurrent use of ovarian suppression is allowed Note: Concurrent use of CDK4/6 inhibitors is not allowed due to cytopenia risk
-
New or worsening self-reported musculoskeletal pain that began or significantly worsened after initiation of AI therapy
-
BPI average pain score of ≥ 4 during screening
-
ECOG PS 0-2
-
Adequate organ function:
- Absolute neutrophil count ≥1,500/µL
- Hemoglobin ≥11.0 g/dL
- Platelet count ≥100,000/µL
- Serum creatinine ≤1.5× upper limit of normal (ULN) or eGFR ≥60 mL/min/1.73m2
- Total bilirubin ≤1.5× ULN (except in patients with documented Gilbert's disease, who must have a total bilirubin < 3.0 mg/dL)
- AST and ALT ≤1.5× ULN
-
Must agree to maintain stable doses of any analgesic medications or other AIMSS related therapies during the study period Note: rescue doses of acetaminophen or ibuprofen allowed on a non-daily basis, unless not new
Exclusion Criteria:
- Current or prior use of hydroxychloroquine or chloroquine within 6 months
- Known hypersensitivity to hydroxychloroquine, chloroquine, or 4-aminoquinoline compounds
- History of retinopathy or retinal vein occlusion issues Note: While there is an association between retinopathy and HCQ use, this occurs rarely and with long term use with higher cumulative doses that used here. Other clinical trials have not required retinal exam (example: CTO-TBCRC04627, approved by IU IRB)
- History of congestive heart failure (any NYHA class)
- QTc prolongation (>450 msec) at screening or history of significant arrhythmias requiring treatment
- Moderate to severe renal impairment (eGFR <60 mL/min/1.73m2)
- Use of a prohibited concomitant medication (refer to Section 6.3.2) that cannot be discontinued or changed to an alternate therapy
- Known glucose-6-phosphate dehydrogenase (G6PD) deficiency
- History of porphyria
- History of psoriasis
- History of antiepileptic medications
- Known history of inflammatory arthritis (example: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis) or connective tissue disease (example: systemic lupus erythematosus, scleroderma, polymyositis)
- Recent initiation or dose change (within 4 weeks) of medications for pain management (NSAIDs, duloxetine, gabapentin, pregabalin, opioids) Note: Patients on stable doses for >4 weeks are eligible
- Patients currently receiving or planned to receive high dose systemic treatment with corticosteroids defined as: cortisone >50mg; hydrocortisone >40mg, prednisone >10mg, methylprednisolone >8mg or dexamethasone >1.5mg; or another immunosuppressive agent Note: Topical or inhaled corticosteroids are allowed
- Other active malignancy other than breast cancer requiring systemic therapy
- Pregnant or lactating
- Co-enrollment in another clinical trial Note: Patients may co-enroll in other clinical trial(s) if the trial(s) does not interfere with the objectives of this trial
- Significant psychiatric illness, in the opinion of the investigator, that would limit compliance with study requirements
- Any active suicidality or history of active suicidal ideation/behavior/attempt within 1 year prior to screening
- Any other condition that, in the opinion of the investigator, would make the patient unsuitable for study participation
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Hydroxychloroquine sulfate
Hydroxychloroquine sulfate, 400 mg orally once daily |
Drug: Hydroxychloroquine sulfate Dose: 400 mg orally once daily Duration: 12 weeks |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
To evaluate the efficacy of hydroxychloroquine
Tijdsspanne: Day 1 and Week 12
|
To evaluate the efficacy of hydroxychloroquine 400 mg daily in reducing joint pain associated with AIMSS as measured by change in Brief Pain Inventory (BPI) Average Pain score (scored from 0-10; a minimally important difference is a 2-point reduction or 30% from baseline). |
Day 1 and Week 12
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of patients achieving a clinically meaningful improvement
Tijdsspanne: Day 1 and Week 12
|
To assess the proportion of patients achieving a clinically meaningful improvement (≥2-point reduction) in BPI Average Pain score. |
Day 1 and Week 12
|
|
Changes in BPI Worst Pain and Pain Interference scores
Tijdsspanne: Day 1 and Week 12
|
To evaluate changes in BPI Worst Pain and Pain Interference scores (scored from 0-10; a minimally important difference is a 2-point reduction or 30% from baseline). |
Day 1 and Week 12
|
|
Changes in endocrine therapy related quality of life
Tijdsspanne: Day 1 and Week 12
|
To assess changes in endocrine therapy related quality of life by FACT-ES (5 point Likert-type scale). |
Day 1 and Week 12
|
|
Changes in grip strength
Tijdsspanne: Day 1 and Week 12
|
To assess changes in grip strength as an objective measure of function using Jamar hand dynamometers (scale of 0-200lbs). |
Day 1 and Week 12
|
|
Patient-reported global impression of change
Tijdsspanne: Week 12
|
To evaluate patient-reported global impression of change using the Patient Global Impression of Change (PGIC) (scale 0-6, 6 being the worst outcome). |
Week 12
|
|
Safety of hydroxychloroquine in this patient population
Tijdsspanne: Day 1, Week 4, Week 12, 30 days post EOT
|
To assess safety of hydroxychloroquine in this patient population using NCI CTCAE v5.0 (grade 1-5, 5 being the worst outcome). |
Day 1, Week 4, Week 12, 30 days post EOT
|
|
Tolerability of hydroxychloroquine in this patient population
Tijdsspanne: Day 1, Week 4, Week 12, 30 days post EOT
|
To assess tolerability of hydroxychloroquine in this patient population via number of patients who completed treatment. |
Day 1, Week 4, Week 12, 30 days post EOT
|
|
Adherence to aromatase inhibitor therapy
Tijdsspanne: Screening, Day 1, and Week 12
|
To evaluate adherence to aromatase inhibitor therapy during the study period via number of patients who completed treatment based on self-report. |
Screening, Day 1, and Week 12
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Tarah Ballinger, MD, IUSCCC
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Pijn
- Neurologische manifestaties
- Musculoskeletale aandoeningen
- Neoplasmata per site
- Neoplasmata
- Gewrichtsziekten
- Huidziektes
- Borst ziekten
- Pathologische aandoeningen, tekenen en symptomen
- Huid- en bindweefselaandoeningen
- Tekenen en symptomen
- Borstneoplasmata
- Artralgie
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Chinolines
- Aminoquinolines
- Chloroquine
- Hydroxychloroquine
Andere studie-ID-nummers
- CTO-IUSCCC-0959
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .